An Efficient High-Throughput Screening Method for MYST Family Acetyltransferases, a New Class of Epigenetic Drug Targets

Epigenetic aberrations are increasingly regarded as key factors in cancer progression. Recently, deregulation of histone acetyltransferases (HATs) has been linked to several types of cancer. Monocytic leukemia zinc finger protein (MOZ) is a member of the MYST family of HATs, which regulate gene expression in cell proliferation and differentiation. Deregulation of these processes through constitutively active MOZ fusion proteins gives rise to the formation of leukemic stem cells, rendering MOZ an excellent target for treating myeloid leukemia. The authors implemented a hit discovery campaign to identify small-molecule inhibitors of MOZ-HAT activity. They developed a robust, homogeneous assay measuring the acetylation of synthetic histone peptides. In a primary screening campaign testing 243 000 lead-like compounds, they identified inhibitors from several chemical classes. Secondary assays were used to eliminate assay-interfering compounds and prioritize confirmed hits. This study establishes a new high-throughput assay for HAT activity and could provide the foundation for the development of a new class of drugs for the treatment of leukemias.

[1]  T. Kundu,et al.  Polyisoprenylated Benzophenone, Garcinol, a Natural Histone Acetyltransferase Inhibitor, Represses Chromatin Transcription and Alters Global Gene Expression* , 2004, Journal of Biological Chemistry.

[2]  A. Kohlmann,et al.  AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features , 2009, Leukemia.

[3]  D. Myszka,et al.  Exploring minimal biotinylation conditions for biosensor analysis using capture chips. , 2010, Analytical biochemistry.

[4]  K. Akashi,et al.  MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. , 2004, Cancer cell.

[5]  R. Roeder,et al.  HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. , 2000, Molecular cell.

[6]  R G Harrison,et al.  New fusion protein systems designed to give soluble expression in Escherichia coli. , 1999, Biotechnology and bioengineering.

[7]  Ricky W. Johnstone,et al.  Epigenetics in cancer: Targeting chromatin modifications , 2009, Molecular Cancer Therapeutics.

[8]  MOZ-TIF2, but Not BCR-ABL, Confers Properties of Leukemic Stem Cells to Committed Murine Hematopoietic Progenitors. , 2004 .

[9]  P. Grant,et al.  NuA4, an essential transcription adaptor/histone H4 acetyltransferase complex containing Esa1p and the ATM‐related cofactor Tra1p , 1999, The EMBO journal.

[10]  M. Maio,et al.  Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications , 2007, Journal of cellular physiology.

[11]  M. Ohki,et al.  Activation of AML1‐mediated transcription by MOZ and inhibition by the MOZ–CBP fusion protein , 2001, The EMBO journal.

[12]  Robert A Copeland,et al.  Mechanistic considerations in high-throughput screening. , 2003, Analytical biochemistry.

[13]  V. Kouskoff,et al.  The histone acetyl transferase activity of monocytic leukemia zinc finger is critical for the proliferation of hematopoietic precursors. , 2009, Blood.

[14]  Ruben Abagyan,et al.  Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. , 2010, Chemistry & biology.

[15]  S. Nutt,et al.  Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells. , 2006, Genes & development.

[16]  J. Baell.  Observations on screening-based research and some concerning trends in the literature. , 2010, Future medicinal chemistry.

[17]  N. Avvakumov,et al.  The MYST family of histone acetyltransferases and their intimate links to cancer , 2007, Oncogene.

[18]  F. Bertucci,et al.  Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases , 2009, Leukemia.

[19]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[20]  Timothy W. Sikorski,et al.  The Human Monocytic Leukemia Zinc Finger Histone Acetyltransferase Domain Contains DNA-binding Activity Implicated in Chromatin Targeting* , 2007, Journal of Biological Chemistry.

[21]  E. Novellino,et al.  Cinnamoyl compounds as simple molecules that inhibit p300 histone acetyltransferase. , 2007, Journal of medicinal chemistry.

[22]  A. Voss,et al.  MYST family histone acetyltransferases take center stage in stem cells and development , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.

[23]  C. Disteche,et al.  The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB–binding protein , 1996, Nature Genetics.

[24]  D. Hilton,et al.  A convenient method for preparation of an engineered mouse interleukin-3 analog with high solubility and wild-type bioactivity , 2010, Growth factors.

[25]  A. Voss,et al.  The Diverse Biological Roles of MYST Histone Acetyltransferase Family Proteins , 2007, Cell cycle.

[26]  D. Rodenhiser,et al.  Epigenetics and human disease: translating basic biology into clinical applications , 2006, Canadian Medical Association Journal.

[27]  A. Voss,et al.  Moz and retinoic acid coordinately regulate H3K9 acetylation, Hox gene expression, and segment identity. , 2009, Developmental cell.